INCR Intercure

InterCure to Participate in Cowen 5th Annual Cannabis Conference

InterCure to Participate in Cowen 5th Annual Cannabis Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate

NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 08, 2022 (GLOBE NEWSWIRE) -- . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will participate in Cowen 5th Annual Cannabis Conference, taking place December 8th, 2022.

Mr. Rabinovitch will take part in the industry leaders panel on Thursday, December 8th, 2022 at 9:30 AM EST, and will be available for 1 on 1 sessions by appointment only.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: .

Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

 



EN
08/12/2022

Underlying

INCRIntercure

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercure

 PRESS RELEASE
Free
INCR INTERCURE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

October 8, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

October 8, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to...

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannab...

September 19, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 mil...

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure’s 16th and 17th consecutive quarter of profitability2.Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensati...

August 29, 2024 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Expansion of its Strategic partnership with Cookie...

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across Germany, through Cookies Corners. This agreement marks an expansion of InterCure and Cookies’ partn...

August 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch